The healthcare sector faced a whirlwind of challenges and opportunities in Q1, from major acquisitions to regulatory uncertainties. What will Q2 bring for biotech and pharma?
Biomarker technologies and digital solutions to address the world’s largest health disorders.
Developing innovative radiopharmaceuticals for a highly underserved oncology sector
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â
